Association of cutaneous anergy with human papillomavirus and cervical neoplasia in HIV-seropositive and seronegative women

AIDS

Volumn 21, Issue 14, 2007, Pages 1933-1941

  Harris, Tiffany G ^a   Burk, Robert D ^a   Xue, Xiaonan ^a   Anastos, Kathryn ^a   Minkoff, Howard ^b   Massad, L Stewart ^c   Young, Mary A ^d   Levine, Alexandra M ^e   Gange, Stephen J ^f   Watts, D Heather ^g   Palefsky, Joel M ^h   Strickler, Howard D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MAIMONIDES MEDICAL CENTER   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anergy; CD4 T lymphocyte count; Cellular immunity; HIV; Human papillomavirus

Indexed keywords

TETANUS TOXOID; VIRUS ANTIGEN; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CANDIDA ALBICANS; CD4+ T LYMPHOCYTE; CLONAL ANERGY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DNA DETERMINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE FUNCTION TEST; IN VIVO STUDY; MAJOR CLINICAL STUDY; MUMPS VIRUS; NEOPLASM; PRIORITY JOURNAL; UTERINE CERVIX TUMOR; WART VIRUS;

ADULT; CARCINOMA, SQUAMOUS CELL; CD4 LYMPHOCYTE COUNT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; INCIDENCE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; PROSPECTIVE STUDIES; RNA, VIRAL; SKIN; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS;

EID: 34548281762     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282c3a945     Document Type: Article

References (46)

1. Bosch FX, De Sanjose S. Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 2003:3-13.
2. Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997; 89:245-250.
3. Clerici M, Shearer GM, Clerici E. Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. J Natl Cancer Inst 1998; 90:261-263.
4. Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, et al. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 2002; 11:483-488.
5. De Jong A, Van Poelgeest MI, Van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJM, et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4R T-cell immunity against early antigens E2 and E6. Cancer Res 2004; 64:5449-5455.
6. Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97:577-586.
7. Palefsky JM, Holly EA. Chapter 6: Immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr 2003; 2003:41-46.
8. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997; 337:1343-1349.
9. Schuman P, Ohmit SE, Klein RS, Duerr A, Cu-Uvin S, Jamieson DJ, et al. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003; 188:128-136.
10. Slovis BS, Plitman JD, Haas DW. The case against anergy testing as a routine adjunct to tuberculin skin testing. JAMA 2000; 283:2003-2007.
11. Kornbluth RS, McCutchan JA. Skin test responses as predictors of tuberculous infection and of progression in HIV-infected persons. Ann Intern Med 1993; 119:241-243.
12. Centers for Disease Control and Prevention. Anergy skin testing and tuberculosis [corrected] preventive therapy for HIV-infected persons: revised recommendations. MMWR Recomm Rep 1997; 46:1-10.
13. Graham NM, Nelson KE, Solomon L, Bonds M, Rizzo T, Scavotto J, et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA 1992; 267:369-373.
14. Birx DL, Brundage J, Larson K, Engler R, Smith L, Squire E, et al. The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. Military Medical Consortium for Applied Retroviral Research. J Acquir Immune Defic Syndr 1993; 6:1248-1257.
15. Blatt SP, Hendrix CW, Butzin CA, Freeman TM, Ward WW, Hensley RE, et al. Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients. Ann Intern Med 1993; 119:177-184.
16. Gordin FM, Hartigan PM, Klimas NG, Zolla-Pazner SB, Simberkoff MS, Hamilton JD. Delayed-type hypersensitivity skin tests are an independent predictor of human immunodeficiency virus disease progression. Department of Veterans Affairs Cooperative Study Group. J Infect Dis 1994; 169: 893-897.
17. Markowitz N, Hansen NI, Wilcosky TC, Hopewell PC, Glassroth J, Kvale PA, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary Complications of HIV Infection Study Group. Ann Intern Med 1993; 119:185-193.
18. Moreno S, Baraia-Etxaburu J, Bouza E, Parras F, Perez-Tascon M, Miralles P, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993; 119:194-198.
19. Huebner RE, Schein MF, Hall CA, Barnes SA. Delayed-type hypersensitivity anergy in human immunodeficiency virus-infected persons screened for infection with Mycobacterium tuberculosis. Clin Infect Dis 1994; 19:26-32.
20. Caiaffa WT, Graham NM, Galai N, Rizzo RT, Nelson KE, Vlahov D. Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection. Arch Intern Med 1995; 155:2111-2117.
21. Janis EM, Allen DW, Glesby MJ, Carey LA, Mundy LM, Gopalan R, Chaisson RE. Tuberculin skin test reactivity, anergy, and HIV infection in hospitalized patients. Longcope Firm of the Osler Medical Housestaff. Am J Med 1996; 100:186-192.
22. Karlsson A, Moberg L, Bratt G, Halvarsson M, Von Krogh G, Morfeldt L, Sandstrom E. An eleven year follow-up of delayed-type hypersensitivity testing for the identification of HIV-1 infected patients at increased risk of developing AIDS. Scand J Infect Dis 1996; 28:125-130.
23. Gourevitch MN, Hartel D, Schoenbaum EE, Klein RS. Lack of association of induration size with HIV infection among drug users reacting to tuberculin. Am J Respir Crit Care Med 1996; 154:1029-1033.
24. Miller WC, Thielman NM, Swai N, Cegielski JP, Shao J, Ting D, et al. Delayed-type hypersensitivity testing in Tanzanian adults with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:303-308.
25. Johnson JL, Nyole S, Okwera A, Whalen CC, Nsubuga P, Pekovic V, et al. Instability of tuberculin and Candida skin test reactivity in HIV-infected Ugandans. The Uganda-Case Western Reserve University Research Collaboration. Am J Respir Crit Care Med 1998; 158:1790-1796.
26. Anastos K, Kalish LA, Palacio H, Benson CA, Delapenha R, Chirgwin K, et al. Prevalence of and risk factors for tuberculin positivity and skin test anergy in HIV-1-infected and uninfected at-risk women. Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 1999; 21:141-147.
27. Anastos K, Shi Q, French AL, Levine A, Greenblatt RW, Williams C, et al. Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004; 35:383-392.
28. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998; 9:117-125.
29. Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91:226-236.
30. Strickler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, Minkoff H, et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003; 95:1062-1071.
31. The Bethesda System for reporting cervical/vaginal cytologic diagnoses: revised after the second National Cancer Institute Workshop, 29-30 April 1991. Acta Cytol 1993; 37:115-124.
32. Munoz N, Bosch FX, De Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527.
33. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6:204.
34. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337:76-84.
35. Ahdieh L, Gange SJ, Greenblatt R, Minkoff H, Anastos K, Young M, et al. Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol 2000; 152:923-933.
36. DHHS/Henry J. Kaiser Family Foundation Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 23 March 2004. http://aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL03232004005.pdf. [accessed: 26 March 2006]
37. Klein RS, Flanigan T, Schuman P, Smith D, Vlahov D. Criteria for assessing cutaneous anergy in women with or at risk for HIV infection. HIV Epidemiologic Research Study Group. J Allergy Clin Immunol 1999; 103:93-98.
38. Carey V, Zeger SL. Modelling multivariate binary data with alertnating logistic regressions. Biometrika 1993; 80:517-526.
39. Kyriakis KP, Balamotis AK, Katsarou-Katsari A, Tosca AD. Recurrent condylomata acuminata: how routine immediate and delayed hypersensitivity parameters might provide a clue to their immunopathogenesis. Eur J Clin Invest 1995; 25:906-909.
40. Hopfl R, Heim K, Christensen N, Zumback K, Wieland U, Volgger A, et al. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 2000; 356:1985-1986.
41. Soumelis V, Scott I, Liu YJ, Levy J. Natural type 1 interferon producing cells in HIV infection. Hum Immunol 2002; 63:1206-1212.
42. Siegal FP, Fitzgerald-Bocarsly P, Holland BK, Shodell M. Interferon-alpha generation and immune reconstitution during antiretroviral therapy for human immunodeficiency virus infection. AIDS 2001; 15:1603-1612.
43. Levi G, Feldman J, Holman S, Salarieh A, Strickler HD, Alter S, Minkoff H. Relationship between HIV viral load and Langerhans cells of the cervical epithelium. J Obstet Gynaecol Res 2005; 31:178-184.
44. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1808-1816.
45. Burns EA, Goodwin JS. Immunology of aging. In: Cassel CK, Leipzig R, Cohen HJ, Larson EB, Meier DE (eds.). Geriatric medicine: an evidence based approach, 4th ed. New York: Springer-Verlag New York, Inc.; 2003. p. 1318.
46. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen O-E, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459-1466.